Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Condensed Consolidated Balance Sheets Statement [Table] Statement [Line Items] Selected Balance Sheet Information Statement Assets [Abstract] Assets Assets, Current [Abstract] Current Assets Cash and Cash Equivalents, at Carrying Value. Cash and cash equivalents Grants Receivable, Current Tax credit receivable Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Assets, Current Total Current Assets Assets, Noncurrent [Abstract] Non-Current Assets Property, Plant and Equipment, Net Total property and equipment, net Property and equipment, net Restricted Cash, Noncurrent Restricted cash Operating Lease, Right-of-Use Asset Right of use asset Intangible Assets, Net (Excluding Goodwill) In-process research and development Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Deposits and Other Assets Noncurrent Deposits and other assets Assets Total Assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current Liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Business Combination, Contingent Consideration, Liability, Current Contingent consideration, current portion Contingent consideration, current portion Employee-related Liabilities, Current Accrued employee benefits Total accrued employee benefits Amount of deferred research and development tax credit that has been received or is receivable, classified as current Deferred Research and Development Tax Credit, Current Deferred research and development tax credit-current portion Loans Payable, Current Loans payable-current Operating Lease, Liability, Current Operating lease liability - current Operating lease liability-current portion Liabilities, Current Total Current Liabilities Liabilities, Noncurrent [Abstract] Non-current Liabilities Business Combination, Contingent Consideration, Liability, Noncurrent Non-current contingent consideration Contingent consideration, net of current portion Loans Payable, Noncurrent Loan Payable - non-current Amount of deferred research and development tax credit that has been received or is receivable, classified as non current. Deferred Research and Development Tax Credit, Noncurrent Non-current deferred research and development tax credit Operating Lease, Liability, Noncurrent Non-current operating lease liability Liabilities Total Liabilities Commitments and Contingencies. Commitments and Contingencies (Note 14) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity: Common Stock, Value, Issued Common stock, $0.001 par value; 350,, shares authorized, 45,921,478 issued and 45,892,668 outstanding at March 31, 2026 and 35,717,159 issued and 35,688,350 outstanding at December 31, 2025 Additional Paid in Capital, Common Stock Additional paid-in capital Treasury Stock, Value Treasury stock at cost, 28,809 shares at March 31, 2026 and at December 31, 2025 Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit). Accumulated deficit Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance Balance Total Stockholders' Equity Liabilities and Equity Total Liabilities and Stockholders' Equity Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Treasury Stock, Shares Treasury stock Condensed Consolidated Statements of Operations and Comprehensive Loss Revenue from Contract with Customer, Excluding Assessed Tax License Revenue Operating Expenses [Abstract] Operating Costs and Expenses: General and Administrative Expense General and administrative Research and Development Expense Research and development Operating Expenses Total Operating Costs and Expenses Operating Income (Loss) Loss from Operations Nonoperating Income (Expense) [Abstract] Other Income: Foreign Currency Transaction Gain (Loss), before Tax Foreign currency exchange (loss) gain Investment Income, Interest Interest income Nonoperating Income (Expense) Total Other Income Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net Loss before income taxes Net Income (Loss) Available to Common Stockholders, Basic Net Loss Attributable to Common Stockholders Net loss attributable to common stockholders Earnings Per Share, Basic Net Loss Per Share - Basic (in dollars per share) Earnings Per Share, Diluted Net Loss Per Share - Dilutive (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted average number of shares outstanding during the period - Basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average number of shares outstanding during the period - Dilutive (in shares) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Loss Net loss Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Gain (loss) on foreign currency translation Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Total comprehensive loss Condensed Consolidated Statements of Stockholder's Equity Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit AOCI Attributable to Parent [Member] Accumulated Other Comprehensive income Treasury Stock [Member] Treasury Stock Shares, Outstanding Balance (in shares) Balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Stock-based compensation Equity impact of the value of new stock issued during the period at the market offering. Stock Issued During Period At Market Offering Value Stock issued under "at-the-market" offering Number of new stock issued during the period at the market offering. Stock Issued During Period At Market Offering Share Stock issued under "at-the-market" offering (in shares) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax Foreign currency exchange gains (losses) Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows From Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation Stock-based compensation Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Change in fair value of contingent consideration The amount of expenses incurred on non-cash lease. Non-Cash Lease Expense Non-cash lease expense Depreciation, Depletion and Amortization Depreciation expense Depreciation Amount of increase (decrease) in deferred research and development tax credit, payable within one year or the normal operating cycle, if longer. Increase (Decrease) in Deferred Research and Development Tax Credit Deferred research and development tax credit Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Employee Related Liabilities Accrued employee benefits Increase (Decrease) in Operating Lease Liability Operating lease liability Net Cash Provided by (Used in) Operating Activities Net Cash Used In Operating Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows from Financing Activities The net amount paid or received by the reporting entity associated with tax credit receivable. Payments for (Proceeds from) Tax Credit Receivable Tax credit receivable Proceeds from (Repayments of) Notes Payable Payment of loans payable The cash inflow from issuance of market offering. Proceeds From Issuance Under At The Market Offering, , Net Of Issuance Costs Proceeds from issuance under at - the - market offering, net of issuance cost Proceeds from Issuance of Long-Term Debt Proceeds from long term debt Net Cash Provided by (Used in) Financing Activities Net Cash provided by Financing Activities Effect of Exchange Rate on Cash and Cash Equivalents Effects of exchange rate changes on cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents and restricted cash at the end of this period Cash and cash equivalents and restricted at the beginning of this period Total cash, cash equivalents, and restricted cash shown in the statement of cash flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet Restricted Cash and Cash Equivalents Restricted cash relating to RETOS loan Restricted cash included in other long-term assets Noncash Investing and Financing Items [Abstract] Supplemental non-cash investing and financing activities: Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Right of use asset obtained in exchange for lease liabilities Organization, Nature of Operations and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization, Nature of Operations and Basis of Presentation n/a. Going Concern Substantial Doubt about Going Concern [Text Block] Going Concern Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Intangibles Intangible Assets Disclosure [Text Block] Intangibles Revenue Revenue from Contract with Customer [Text Block] Revenue Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Fair Value of Financial Instruments n/a Research and Development Tax Credits The federal research and development (R&D) tax credit results in a dollar for dollar reduction in a company's tax liability for certain domestic. Research and Development Tax Credits [Text Block] Research and Development Tax Credits No definition available. Selected Balance Sheet Information Supplemental Balance Sheet Disclosures [Text Block] Selected Balance Sheet Information Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Stock Warrants The entire disclosure for stock warrants. Stock Warrants Disclosure [Text Block] Stock Warrants Net Loss per Share Earnings Per Share [Text Block] Net Loss per Share Common and Stock Stockholders' Equity Note Disclosure [Text Block] Common and Stock Loans Payable Debt Disclosure [Text Block] Loans Payable Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Related Party Related Party Transactions Disclosure [Text Block] Related Party N/A License Agreements The entire disclosure for information about license agreement. License Agreement Disclosure [Text Block] License Agreements Subsequent Events Subsequent Events [Text Block] Subsequent Events Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Segment Reporting, Policy [Policy Text Block] Segment information In Process Research and Development, Policy [Policy Text Block] IPR&D Disclosure of accounting policy for completed business combinations, Contingent consideration (purchase method, acquisition method or combination of entities under common control). Business Combinations Policy, Contingent Consideration, Policy [Policy Text Block] Contingent Consideration Disclosure of accounting policy for long-lived assets include property, equipment and right-of-use assets. Long Lived Assets For Assets Property Equipment And Right Of Use Assets, Policy [Policy Text Block] Long-Lived Assets Impairment Disclosure of accounting policy for research and development tax credit. Research And Development Tax Credit Policy [Policy Text Block] Research and Development Tax Credits New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements and Developments Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Schedule of in-process R&D Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of change in fair value as determined by Level 3 inputs for the contingent consideration liabilities Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Schedule of fair value of financial instruments measured on a recurring basis Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of fair value measurements of contingent consideration for which a liability is recorded Tabular disclosure of the carrying amounts of prepaid expenses and other current assets. Schedule of Prepaid Expenses And Other Current Assets [Table Text Block] Schedule of prepaid expenses and other current assets Property, Plant and Equipment [Table Text Block] Schedule of property and equipment, net Tabular disclosure of accrued expenses. Accrued Expenses [Table Text Block] Schedule of accrued expenses Tabular disclosure of information related to accrued employee benefits. Accrued Employee Benefits [Table Text Block] Schedule of accrued employee benefits Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions used for estimating fair value Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option activity Tabular disclosure of warrant activity. Schedule Of Warrant Activity [Table Text Block] Summary of all warrant activity Schedule of Debt [Table Text Block] Schedule of debt Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of maturity analysis of debt Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of maturity analysis of operating leases Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-Based Compensation Stock Warrants Number of Operating Segments Number of operating segments Number of Reportable Segments Number of reportable segments Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value of Financial Instruments Going Concern Restructuring and Related Cost, Number of Positions Eliminated Workforce reduction Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Percent of workforce reduction Severance Costs Charges in relation to the workforce reduction Amount of estimated annual cost expected to save in employee compensation and benefits under the restructuring plan. Restructuring and Related Cost, Expected Annual Compensation and Benefits, Savings Expected annual compensation and benefits savings Schedule of Revenues from External Customers and Long-Lived Assets [Table] Geographical [Axis] Geographical [Domain] UNITED STATES United States SPAIN Spain Revenues from External Customers and Long-Lived Assets [Line Items] Summary of Significant Accounting Policies Long-Lived Assets Long-lived assets Summary of Significant Accounting Policies [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] In Process Research and Development [Member] In-process R&D Guarantor Obligations, Nature [Axis] Guarantor Obligations, Nature [Domain] Research and Development Arrangement [Member] Research and Development Program Summary of Significant Accounting Policies [Line Items] Summary of Significant Accounting Policies Amount of accumulated impairment loss resulting from write-down of asset. Intangible Assets, Indefinite-Lived (Excluding Goodwill), Impaired, Accumulated Impairment Loss Impairments Asset Impairment Charges Impairment charge Research and development expenditure period. Research And Development Expenditure Period Research and development expenditure period (in months) Intangible Asset, Indefinite-Lived [Table] Indefinite-Lived Intangible Assets [Line Items] In-process R&D Indefinite-Lived Intangible Assets [Roll Forward] Indefinite-Lived Intangible Assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Balance at the end Balance at the beginning Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Effects of exchange rates Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) In-process research and development impairment Disaggregation of Revenue [Table] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Represents the information pertaining to license agreement with Rasayana Therapeutics, Inc. License Agreement With Rasayana Therapeutics, Inc. [Member] License agreement with Rasayana Therapeutics, Inc. Disaggregation of Revenue [Line Items] Revenue Amount of cash inflow from upfront payments received by the entity pursuant to agreement. Proceeds From Upfront Payment Upfront payments received Amount of development milestone payment receivable pursuant to the agreement. Development Milestone Payment Receivable Potential development milestone payments Amount of sales milestone payment receivable pursuant to the agreement. Sales Milestone Payment Receivable Potential sales milestone payments Fair Value Measurement Inputs and Valuation Techniques [Table] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] This member stands for the information pertaining to VCN Biosciences S. L. VCN [Member] VCN Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Operating Expense [Member] Operating Expense Scenario [Axis] Scenario, Unspecified [Domain] Represents the member information pertaining to the amount to be paid by the end of August 2025. Paid by End Of August 2025 [Member] Paid by end of August 2025 Represents the member information pertaining to the amount to be paid by the end of December 2025. Paid by End Of December 2025 [Member] Paid by end of December 2025 Represents the information pertaining to scenario where the licensing or business development transaction is secured. Licensing Or Business Development Transaction Is Secured [Member] Licensing or business development transaction is secured Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value of Financial Instruments Amount of additional consideration paid on a business combination upon achievement of milestones. Business Combination, Contingent Consideration Arrangements, Additional Amount Paid On Achievement Of certain Milestones Additional consideration related to the achievement of certain milestones Amount paid due to approval. Amount to be paid due to approval Amount to be paid due to approval Milestone amount obligated to pay as a result of achieving the certain milestone being the achievement of the primary survival and safety endpoints in the Phase 2b of clinical trial. Business Combination, Contingent Consideration Payable On Achieving Certain Milestone Amount of milestone obligated to pay as a result of achieving certain milestone Milestone amount paid as a result of achieving the certain milestone being the achievement of the primary survival and safety endpoints in the Phase 2b of clinical trial. Business Combination, Contingent Consideration Paid on Achieving Certain Milestone Amount of milestone payment paid as a result of achieving certain milestone Number of milestone payments in pursuant to achievement of certain milestone. Business Combination Contingent Consideration Arrangements, Number Of Milestone Payments Number of milestone payments Payments to be made after initiating patient dosing in the US and phase 2 clinical trial. Payment Made After Clinical Trial Payment made after clinical trial Business Combination, Contingent Consideration, Liability Fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Increase in operating expense Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 Fair value measurement, transfer in to level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 Fair value measurement, transfer out of level3 Reclassification of amounts to accrued expenses due to milestone being achieved Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liability Class [Axis] Fair Value by Liability Class [Domain] Commitments [Member] Contingent consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value of Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Balance at ending Balance at beginning Balance at ending Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in fair value Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 3 [Member] Level 3 Financial Liabilities Fair Value Disclosure Fair value of liabilities Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Discount Rate [Member] Discount rate Measurement input using Weighted average discount rate. Weighted Average Discount rate [Member] Weighted Average Discount rate Measurement input using Probability of Occurrence. Probability Of Occurrence [Member] Probability of Occurrence (periodic for each Milestone) Measurement input using Probability of Occurrence Cumulative. Probability Of Occurrence. [Member] Probability of occurrence (cumulative through each Milestone) Range [Axis] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Derivative Liability, Measurement Input Contingent consideration, measurement Input Schedule of Guarantor Obligations [Table] Guarantor Obligations [Line Items] Research and Development Tax Credits Amount of deferred research and development tax credit grant receivable. Deferred Research and Development Tax Credit, Grant Receivable Deferred research and development tax credit grant receivable. Amount of deferred research and development tax credit related to Offset. Deferred Research And Development Tax Credit Offset Research and development off set Amount of cash inflow from Research and Development rebate program sponsored by the Spanish government. Proceeds From Research And Development Program Reimbursement amount Sum of the amount paid in advance for consulting, subscriptions and other expenses. Prepaid Consulting Subscriptions And Other Expenses Prepaid consulting, subscriptions and other expenses Prepaid Insurance Prepaid insurance Value Added Tax Receivable, Current VAT receivable Carrying amount as of the balance sheet date of receivables due on at-the-market stock sales that have not cash settled prior to period end. Stock Sales Receivable, Current Stock sales receivable Other Receivables, Net, Current Other receivable Other Receivable, after Allowance for Credit Loss, Current, Related Party [Extensible Enumeration] Amount of Prepaid Manufacturing Expense. Prepaid Manufacturing Expense Prepaid manufacturing expenses Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Computers and office equipment [Member] Computers and office equipment Other Property, Plant and Equipment [Member] Other property, plant and equipment Leasehold Improvements [Member] Leasehold improvements Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks. Computer Software [Member] Software Property, Plant and Equipment [Line Items] Selected Balance Sheet Information Property, Plant and Equipment, Gross Total property and equipment, gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Carrying value as of the balance sheet date of obligations incurred through that date and payable for accomplishing milestone. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Milestone Payments Accrued milestones payments The carrying value of accrued clinical consulting services payable as on balance sheet date. Accrued Clinical Consulting Services Accrued clinical consulting services The manufacturing costs incurred in the production of goods for sale. Accrued manufacturing costs Accrued manufacturing costs Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments. Accrued Vendor Payments Accrued vendor payments Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued expenses Total accrued expenses Accrued Employee Benefits, Current Accrued compensation expense Accrued Vacation, Current Accrued vacation expense Accrued Bonuses, Current Accrued bonus expense Plan Name [Axis] Plan Name [Domain] 2010 Stock Plan [Member] 2010 Stock Plan Represents information pertaining to 2020 Stock Plan. 2020 Stock Plan [Member] 2020 Stock Plan Related Party [Axis] Related Party [Domain] n/a. Consultant [Member] Consultant General and Administrative Expenses and Research and Development Expense [Member] General and administrative expenses and research and development expense Sale of Stock [Axis] Sale of Stock [Domain] Employee Stock [Member] Employees Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Share-based compensation arrangement by share-based payment award, number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options, Ending balance Options, Beginning balance Share-based payment award, options, outstanding, number Number of stock expired on granted period Share-Based Compensation Arrangement by Share-Based Payment Award, Grant, Expirations in Period Share-based payment award, options, grants, expired period Number of options issued, including both vested and non-vested options. Share Based Compensation Arrangement By Share Based Payment Award Options Issued Number Shares Share-based payment award, options, issued, number Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Share-based compensation arrangement by share-based payment award, shares issued Allocated Share-based Compensation Expense Allocated share-based compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized stock-based compensation expense Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options, Granted (in shares) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Granted Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life of option (years) Stock Option Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Options, Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price, Ending balance Weighted Average Exercise Price, Beginning balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Exercisable Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value Grant date fair value of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value Class of Treasury Stock [Table] Represents the member information pertaining to May 2025 public offering (the "Offering"). May 2025 Public Offering [Member] May 2025 public offering Represents the member information pertaining to September 2024 public offering (the "Offering"). September 2024 Public Offering [Member] September 2024 public offering Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents the information pertaining to pre-funded warrants. Pre-Funded Warrants [Member] Pre-funded warrants Represents the information pertaining to common warrants. Common Warrants [Member] Common Warrants Represents the information pertaining to May warrants and September warrants. Existing Warrants [Member] Existing Warrants Represents information pertaining to new common stock purchase warrants. New Common Stock Purchase Warrants [Member] New Warrants Warrant [Member] Warrants Equity, Class of Treasury Stock [Line Items] Stock Warrants Stock Issued During Period, Shares, New Issues Issuance of Common Stock and Warrants, net of issuance costs ( in shares) Stock issued during period (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of warrants to purchase shares Per share or per unit amount of equity securities and warrants issued. Share and Warrants, Offering Price Offering price Proceeds from Issuance or Sale of Equity Gross proceeds Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Class of warrant or right, number of securities called by each warrant or right Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price per warrant Warrants and Rights Outstanding, Term Expected life of warrant (years) The maximum percentage of shares outstanding that is owned by the holder of warrants, beyond which the warrants cannot be exercised. Threshold Percentage of Shares Outstanding for Exercise of Warrants Percentage of shares outstanding for exercise of warrants Number of days of prior notice from the holder to increase the amount of beneficialownership of outstanding shares, after giving effect to the exercise. Notice Period to Increase Beneficial Ownership Notice period The percentage of outstanding shares exceeding which a prior notice from holder to exercise the warrants to increase the amount of beneficial ownership. Threshold Percentage of Shares Outstanding for Exercise of Warrants Requiring Prior Notice Threshold percentage of shares outstanding for exercise of warrants Shares of stock issued as a result of the exercise of warrants. Stock Issued During Period Shares Warrants Exercised Warrants exercised Per share or per unit amount of warrants issued. Warrants, Offering Price Warrants, offering price The maximum percentage of shares outstanding that is owned by the holder of warrants, beyond which the warrants cannot be exercised at the election of the holder. Threshold Percentage of Shares Outstanding for Exercise of Warrants at the Election of Holder Percentage of shares outstanding for exercise of warrants at the election of holder Number of share warrants exercised during the period. Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Number of Warrants, Exercised Number of warrants exercised Percentage of shares of common stock underlying existing warrants that were issued as new warrants under an inducement agreement. Class Of Warrant Or Right, Inducement Premium Percentage of shares of common stock underlying existing warrants Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of Warrants, Ending balance Number of Warrants, Beginning balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Number of Warrants, Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted Average Exercise Price, Ending balance Weighted Average Exercise Price, Beginning balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Exercise Price, Granted Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period. Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value Weighted Average Exercise Price, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Weighted Average Remaining Contractual Life (in years) Weighted average remaining contractual term for equity-based awards granted excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted, Weighted Average Remaining Contractual Terms Weighted Average Remaining Contractual Life, Granted (in years) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Derivative Instrument [Axis] Derivative Contract [Domain] Options Options Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net Loss per Share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of options and warrants for the purchase of common stock that were excluded from the computations of net loss per common share Schedule reflecting stockholders equity. Stockholder's Equity [Table] Represents the information pertaining to at the market offering.. At the market offering [Member] ATM Sales Agreement Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Stockholder's Equity [Line Items] Common and Preferred Stock Proceeds from Issuance of Common Stock Schedule of Capitalization, Long-term Debt [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Unsecured Debt [Member] Unsecured loan Schedule of Capitalization, Long-term Debt [Line Items] Loans Payable Debt Instrument, Interest Rate, Effective Percentage Loans acquired, interest rate Government Assistance, Award Amount Government assistance, award amount Debt Instrument, Face Amount Unsecured loan amount Debt Instrument, Interest Rate, Stated Percentage Interest rate Debt Instrument, Term Repayment term Interest Expense, Debt Interest expense Schedule of Capitalization [Table] Derivative Financial Instruments, Liabilities [Member] NEBT Loan Represents information pertaining to RETOS 2015. Retos 2015 [Member] RETOS 2015 Represents information pertaining to THERICEL Loan. THERICEL LOAN [Member] THERICEL Loan Schedule of Capitalization [Line Items] Loans Payable Long-Term Debt, Maturity, Remainder of Fiscal Year 2026 Long-Term Debt, Maturity, Year One 2027 Long-Term Debt, Maturity, Year Two 2028 Long-Term Debt, Maturity, Year Three 2029 Long-Term Debt, Maturity, Year Four 2030 Long-Term Debt, Maturity, After Year Four Thereafter Long-term Debt Total Disclosure of information about commitments and contingencies. Commitments And Contingencies Disclosure [Table] Represents the information pertaining to U.S and Spanish facilities. Us And Spanish Facilities [Member] Us And Spanish Facilities Represents the information pertaining to research and office facilities in Parets del Valls, Barcelona, Spain. Research And Office Facilities, Parets del Valls, Barcelona, Spain [Member] Research And Office Facilities, Parets del Valls, Barcelona, Spain Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Commitments And Contingencies Disclosure [Line Items] Commitments and Contingencies Lessee, Operating Lease, Renewal Term Renewed lease term Duration of lease rent abatement. Lease Rent Abatement Period 1 Lease rent abatement period Percentage of office leases owned by subsidiary. Percentage of Office Leases Owned By Subsidiary Percentage of office leases owned by subsidiary Term of lessee's operating lease short term agreements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Lessee, Operating Lease, Short Term Agreement Term Termination notice period (in days) Term of lessee's operating lease additional renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Lessee, Operating Lease, Additional Renewal Term Additional lease renewal term Operating Lease, Cost Operating lease cost Operating Lease, Payments Operating lease payments Operating Lease, Weighted Average Remaining Lease Term Remaining lease term Operating Lease, Weighted Average Discount Rate, Percent Operating Lease weighted average discount rate Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2026 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2027 Lessee, Operating Lease, Liability, Payments, Due Year Two 2028 Lessee, Operating Lease, Liability, Payments, Due Year Three 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four 2030 Lessee, Operating Lease, Liability, to be Paid, Year Five 2031 Lessee, Operating Lease, Liability, Payments, Due Total Lessee, Operating Lease, Liability, Undiscounted Excess Amount Discount factor Operating Lease, Liability, Statement of Financial Position [Extensible List] Operating Lease, Liability Operating lease liability Schedule of Related Party Transactions, by Related Party [Table] Title of Individual [Axis] Relationship to Entity [Domain] Board of Directors [Member] Board of Directors Directors Related Party [Member] Related Party Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to Ms. Shallcross. MaryAnn Shallcross [Member] Ms. Shallcross Related Party Transaction [Line Items] Related Party Amount of compensation that is agreed to be paid for the director. Approved Compensation Payable Approved compensation The amount of approved bonus payable as at the end of the reporting period. Approved Bonus Payable Approved bonus payable Compensation Expense, Excluding Cost of Good and Service Sold Compensation paid Number of employees terminated in workforce reduction. Number of Employees Terminated Number of employees terminated in workforce reduction Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] License Agreements Threshold period within which breach has to be cured to prevent termination of agreement. Termination Of Agreement, Threshold Cure Period For Material Breach Period of termination of agreement Number of additional periods to cure breach for preventing termination of agreement. Termination Of Agreement, Cure Period For Material Breach, Number Of Additional Period Number of additional periods for termination of agreement. Threshold additional period within which breach has to be cured to prevent termination of agreement. Termination Of Agreement, Threshold Additional Cure Period For Material Breach Additional period within which breach has to be cured to prevent termination Duration of license termination written notice period. License Termination Written Notice Period License termination The maximum allowable duration for which material development activities may be suspended before the entity becomes entitled to exercise its termination rights under the Agreement. Termination Of Agreement, Threshold Period For Suspension Of Material Development Efforts Maximum allowable Period